600216 浙江医药
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,190,865-2.86%8,880,6029,375,2177,794,1468,115,805
减:营业总成本1,909,3907.39%7,817,2137,934,0247,681,6667,482,025
    其中:营业成本1,422,85411.45%5,801,8645,406,5415,269,8795,318,274
               财务费用37,330-191.68%(72,972)(4,958)(17,488)(37,966)
               资产减值损失1,445-103.57%(202,120)(263,899)(137,208)(117,141)
公允价值变动收益(654)-69.54%4,642(21,534)(10,099)(23,881)
投资收益11,20038.61%2,580(8,069)(3,505)(32,626)
    其中:对联营企业和合营企业的投资收益(2,819)14.71%(9,347)(9,643)(9,782)(3,806)
营业利润306,354-32.56%962,9301,223,110380,158504,616
利润总额306,451-32.47%951,7291,212,282363,279491,388
减:所得税费用48,090-29.83%191,490192,03186,485128,775
净利润258,362-32.94%760,2391,020,252276,794362,614
减:非控股权益(28,651)20.22%(113,141)(140,259)(152,845)(176,956)
股东净利润287,012-29.84%873,3801,160,511429,640539,570

市场价值指针
每股收益 (元) *0.300-30.23%0.9101.2100.4500.560
每股派息 (元) *----0.2800.3700.1500.170
每股净资产 (元) *11.6891.56%11.38011.0739.9809.594
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容